Want to see FBRX full AI Analyst Report?
FBRX Stock Chart & Stats
$54.78
-$4.92(-8.24%)
At close: 4:00 PM EDT
$54.78
-$4.92(-8.24%)
Day’s Range― - ―
52-Week Range$10.11 - $77.20
Previous CloseN/A
Volume575.89K
Average Volume (3M)97.46K
Market Cap
$1.63B
Enterprise Value$307.03
Total Cash (Recent Filing)$198.46M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.59
Shares Outstanding21,229,088
10 Day Avg. Volume83,173
30 Day Avg. Volume97,456
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)6.58
Price to Sales (P/S)0.00
P/FCF Ratio-7.87
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.03
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$76.60Price Target Upside39.83% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-3.93
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic AcquisitionThe acquisition provides strategic validation for FB102 and places Forte's lead program within a larger immunology platform, potentially improving development resources and access to capabilities needed to advance autoimmune therapies.
Clinical Proof Of ConceptPositive controlled clinical data reduce development uncertainty and support FB102's therapeutic potential. The observed efficacy, durability and safety profile also strengthen the program's broader autoimmune development rationale.
Debt-Free Balance SheetA debt-free capital structure limits interest and refinancing risk while giving management greater flexibility during clinical development. The larger asset and equity base also indicates improved capitalization versus 2025.
Bears Say
No Commercial RevenueThe absence of product revenue leaves Forte dependent on clinical progress and financing rather than operating income. Widening losses show that expenses are increasing without commercial scale to absorb the cost base.
Persistent Cash BurnOngoing negative cash generation means Forte must continue consuming capital to fund trials and operations. This can pressure liquidity over time and increase reliance on external funding before a revenue base develops.
Clinical-Stage Execution RiskForte's value remains concentrated in clinical-stage programs, including FB102, with no established commercial portfolio. Trial delays, safety findings or weaker later-stage results could materially limit future revenue and funding access.
Forte Biosciences News
FBRX FAQ
What was Forte Biosciences Inc.’s price range in the past 12 months?
Forte Biosciences Inc. lowest stock price was $10.11 and its highest was $77.20 in the past 12 months.
What is Forte Biosciences Inc.’s market cap?
Forte Biosciences Inc.’s market cap is $1.63B.
When is Forte Biosciences Inc.’s upcoming earnings report date?
Forte Biosciences Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 84 days.
How were Forte Biosciences Inc.’s earnings last quarter?
Forte Biosciences Inc. released its earnings results on Aug 17, 2026. The company reported -$0.981 earnings per share for the quarter, beating the consensus estimate of -$1.03 by $0.049.
Is Forte Biosciences Inc. overvalued?
According to Wall Street analysts Forte Biosciences Inc.’s price is currently Undervalued.
Does Forte Biosciences Inc. pay dividends?
Forte Biosciences Inc. does not currently pay dividends.
What is Forte Biosciences Inc.’s EPS estimate?
Forte Biosciences Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Forte Biosciences Inc. have?
Forte Biosciences Inc. has 21,229,088 shares outstanding.
What happened to Forte Biosciences Inc.’s price movement after its last earnings report?
Forte Biosciences Inc. reported an EPS of -$0.981 in its last earnings report, beating expectations of -$1.03. Following the earnings report the stock price went up 0.078%.
Which hedge fund is a major shareholder of Forte Biosciences Inc.?
Currently, no hedge funds are holding shares in FBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Forte Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$76.60 (39.83% Upside)
$76.60 (39.83% Upside)
Blogger Sentiment
Neutral
FBRX Sentiment 56%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 380.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
90.89%
Trailing 12-Months
Company Description
Forte Biosciences Inc.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
FBRX Stock 12 Month Forecast
Average Price Target
$76.60
▲(39.83% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protalix
―
Protara Therapeutics
―
Innate Pharma
―
Ownership Overview
1.77% Insiders
19.96% Mutual Funds
49.31% Other Institutional Investors
19.49% Public Companies and
Individual Investors